Clinical trials: Insulin, completed
Primary Insulin Hypersecretion, Obesity
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
This study is in patients with at least moderate obesity (Body Mass Index [BMI] > 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar as fat).
- Trial name
- NCT00094146
- Testing
- Sandostatin LAR Depot
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Novartis
Type 2 Diabetes
TODAY2 Phase 2 Follow-up
The primary objective of T2P2 is to track the progression of T2D and related comorbidities and complications in the TODAY cohort as they transition to young adulthood.
- Trial name
- T2P2 (NCT02310724)
- Testing
- TODAY cohort
- Where
- 15 sites in United States
- Volunteers
- 517 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02479022
- Testing
- Insulin 320, insulin glargine
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)
Investigation into patients with type 2 diabetes mellitus not achieving adequate glycemic control while treated with combination of premixed insulin analogue formulations twice daily and metformin will be randomly assigned to…
- Trial name
- S019 (NCT00393705)
- Testing
- Insulin Biphasic Aspart 30/70, insulin lispro LM, insulin lispro MM
- Where
- 9 sites in Croatia, Poland and 3 more
- Volunteers
- 302 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
PS230005 Control-IQ 1.5 Post-Approval Study
This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to <6 years old.
- Trial name
- NCT06717451
- Testing
- Control-IQ Technology v1.5
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 2 Diabetes
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus
A multi-year clinical study to improve tools for measuring the function of insulin-producing beta cells in people with type 2 diabetes mellitus.
- Trial name
- NCT01663220
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Foundation for the National Institutes of Health
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)
The aim of this study is to learn more about how physical activity and cardiorespiratory fitness are related to diabetes risk among breast cancer patients prescribed an endocrine therapy.
- Trial name
- ABIDE (NCT06830486)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
Hypertension, Impaired Glucose Tolerance
Telmisartan and Losartan in Hypertensive IGT
Inhibition of RAS delays onset of diabetes in clinical studies. Preliminary evidence suggests that telmisartan may have unique metabolic properties compared to other ARB due to activation of PPARγ.
- Trial name
- NCT00407862
- Testing
- Telmisartan 80 mg, Losartan 50 mg
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Medical University of Graz
Esophageal Cancer, Nutrition Disorders
Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
The incidence of oesophagogastric cancer has increased by 400% since the 1970s in Ireland and the United Kingdom. In addition, refinement of perioperative management and the now widespread use of multimodal protocols for patients…
- Conditions
- Esophageal Cancer, Nutrition Disorders, Appetite Disorders, Dumping Syndrome
- Trial name
- EndoGut (NCT03734627)
- Testing
- Octreotide Acetate, Saline Solution, Paracetamol
- Where
- 2 sites in Ireland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- St. James's Hospital, Ireland
Diabetes, Obese
Mitochondrial Dysfunction in Diabetes
The purpose of this study is to determine whether insulin resistance is accompanied by "exercise resistance". Investigators will use mass spectrometry and proteomics analysis to test the hypothesis is that a bout of exercise that…
- Trial name
- PGC-1 (NCT01724502)
- Testing
- Exercise and muscle biopsies
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Mitochondrial Respiratory Chain Deficiencies
Abdominal Adiposity and Muscle Mitochondrial Functions
Numerous studies have demonstrated that excess perivisceral adipose tissue is associated with metabolic diseases such as insulin resistance.
- Trial name
- Mithycal (NCT00446745)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Hypertension
Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)
To determine if angiotensin-II AT-1 receptor blockade(ARB) may improve insulin sensitivity assessed by the hyperinsulinaemic isoglycaemic glucose clamp, more than CCB therapy at a comparable dose with regards to the blood…
- Trial name
- NCT00237588
- Testing
- Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- Ullevaal University Hospital
Diabetes Mellitus, Type 2
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D).
- Trial name
- NCT06403761
- Testing
- Semaglutide, Cagrilintide
- Where
- Germany
- Volunteers
- 158 people
- Sponsor
- Novo Nordisk A/S
Gestational Diabetes Mellitus in Pregnancy
Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus
Gestational diabetic mellitus (GDM) patients randomised to metformin or insulin group.Aim was to achieve blood sugar levels of Blood sugar fasting (BSF) <5.3 mmol/l and 1 hour post meal<7.8mmol/l.
- Trial name
- NCT03320694
- Testing
- Metformin, Insulin
- Where
- Pakistan
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Type 2 Diabetes Mellitus
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily…
- Trial name
- VIVID (NCT02561078)
- Testing
- Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 420 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Advancing Insulin Prescribing in General Practice
Family Physicians, the subjects of this trial are reluctant to initiate insulin in patients with type 2 diabetes due to a lack of familiarity and comfort with this clinical strategy.
- Trial name
- AIM@GP (NCT00593489)
- Testing
- Basal Insulin Initiation Strategy
- Where
- Canada
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Stroke, Insulin Resistance
Trial of Aerobic Exercise Training in Stroke Survivors
The purpose of this study is to examine the effects of treadmill training on inflammation in the skeletal muscle and adipose tissue, insulin action in the skeletal muscle, and whole body glucose metabolism in stroke survivors.
- Conditions
- Stroke, Insulin Resistance, Sedentary Lifestyle
- Trial name
- NCT00891514
- Testing
- Aerobic Exercise, Stretching
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Baltimore VA Medical Center
Obesity
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be…
- Trial name
- NCT00131378
- Testing
- Nutropin AQ growth hormone
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below…
- Trial name
- GALAPAGOS (NCT01121835)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE, PREMIXED INSULIN
- Where
- 96 sites in Austria, Brazil and 14 more
- Volunteers
- 934 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.